We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at where Revelation Biosciences Inc. (NASDAQ:REVB) stands against other stocks that fall behind amid market optimism.

Wall Street’s main indices rebounded from hefty losses on Wednesday after President Donald Trump announced that the US will pause the imposition of higher tariffs on 75 countries for 90 days.

In a post on Truth Social, Trump said that more than 75 countries have called to negotiate and have not retaliated in any way.

“I have authorized a 90-day PAUSE, and a substantially lowered Reciprocal Tariff during this period, of 10%, also effective immediately,” he noted.

Following the announcement, the Dow Jones jumped by 7.87 percent, the S&P 500 surged by 9.52 percent, and the tech-heavy Nasdaq soared by 12.16 percent.

Despite the overall market optimism, 10 companies, predominantly in the biopharmaceutical sector, registered losses amid the lack of fresh developments to spark buying appetite.

In this article, we listed Wednesday’s 10 worst performers and detailed the reasons behind their drop.

To come up with the list, we considered only the stocks with over $1 million in trading volume.

A scientist in a lab coat examining a sample of cells through a microscope, illuminated by the bright laboratory lights.

Revelation Biosciences Inc. (NASDAQ:REVB)

Revelation Biosciences dropped by 13.28 percent on Wednesday to close at $3.2 apiece as investors sold off positions for higher-yielding assets amid the lack of fresh developments.

In recent news, REVB announced positive results in the clinical trials for REVTx-300 and  REVTx-100 for the potential treatment of acute and chronic organ disease and the prevention and treatment of infection.

According to the company, the studies, under what it named the Gemini project, showed a reduction in the inflammatory response in human peripheral blood mononuclear cells (PBMCs) that were exposed to clinically relevant molecules on inflammation.

Human PBMCs were primed with either Gemini or placebo followed by a challenge with clinically relevant promoter molecules of inflammation including high mobility box protein-1 (HMGB-1) and lipopolysaccharide (LPS) in vitro.

Overall, REVB ranks 4th on our list of stocks that fall behind amid market optimism. While we acknowledge the potential of REVB as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than REVB but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.